Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.71% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTSTANDARD BIOTOOLS INC.'s latest supported as-filed period reports revenue of $20.1M; gross margin moved 357 basis points higher on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.71% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -51.29% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -7.62% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 85.07% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 52.40% · CORE
Level · gp.fundamentals.operating_margin
Raw value -126.28% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +70.2% from the comparable as-filed period.
Gross margin changed +357 basis points from the comparable as-filed period.
Gross profit changed -0.9% from the comparable as-filed period.
Inventory changed -29.2% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
LAB · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-363767SEC ↗4Aug 24, 2026Period Aug 20, 20260001193125-26-363762SEC ↗4Aug 24, 2026Period Aug 20, 20260001193125-26-363758SEC ↗10-QAug 5, 2026Period Jun 30, 20260001193125-26-335103SEC ↗8-KAug 5, 2026Period Aug 5, 20260001193125-26-335106SEC ↗4Aug 4, 2026Period Aug 3, 20260001193125-26-333225SEC ↗8-K/AJul 29, 2026Period Jul 28, 20260001140361-26-029964SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 20, 2026Filed Aug 24, 2026 | Mackay SeanSVP & Chief Business Officer | Tax WithholdingDirect | 25,729 | $1 | $17,290 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 9.83% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 20.15% · OPTIONAL
Net income changed +20.0% from the comparable as-filed period.
Operating income changed +1.2% from the comparable as-filed period.
Operating margin changed -820 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001140361-26-029841